Sign in
CompletedPhase 4

Intranasal Steroid as Medical Therapy For Sleep-Disordered Breathing in Children

Key facts

Who runs it
Murdoch Childrens Research Institute
Where
Australia2 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 4
People taking part
130 people enrolled
Started
5 Dec 2022
Ended
17 Jul 2025
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Mometasone Furoate 50mcg Nasal Spray
  • Sodium Chloride 0.9 % Nasal Spray
Record updated
30 September 2025

Who can take part

Age
3 years to 12 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • Each participant must meet all of the following criteria to be enrolled in this trial:
  • Is between the ages of 3 and 12 years inclusive at the time of randomisation
  • Has symptoms of Sleep Disordered Breathing (SDB) as determined by a Brouillette score ≥ -1 on telehealth/phone screening
  • Has a legally acceptable representative capable of understanding the informed consent document and providing consent on the participant's behalf

Who cannot take part

  • Has a prior diagnosis of craniofacial, neuromuscular, syndromic or defined genetic disorders
  • Has active tonsillitis or nasal infection (must be resolved prior to randomisation)
  • Has used oral, intravenous, or intranasal steroids in the past 6 weeks. (Inhaled steroids for asthma will be allowed concomitantly during the study)
  • Is known to require systemic steroids prior to the completion of the study treatment phase
  • Has had treatment with any other investigational drug within 6 months prior to randomisation
  • Has a history of tonsillectomy and/or adenoidectomy
  • Has a history of haemorrhagic diathesis or recurrent (daily) or severe epistaxis
  • Has a history of nasal surgery or trauma which has not fully healed
  • Has a known hypersensitivity to the study drug or its formulation
  • Has a BMI over the 97th centile for age and gender
  • Participants meeting any of the following criteria will be excluded from the study:
  • Is assessed to have stertor (snoring) while awake at rest
  • Daily use of antihistamine or decongestant nasal sprays
  • Is unable to provide consent without the aid of an interpreter
  • In the opinion of the Investigator may be unable to follow the protocol

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

MIST+ is studying a nasal spray to see if it will reduce the need for surgery for snoring. Children aged 3-12 are invited to take part. Snoring affects up to 10% of children and can cause sleeping problems and concentration or behavioural issues in the daytime. Currently the most common treatment for snoring is surgery to remove the tonsils and/or adenoids, however many children wait a long time to see a specialist. This research is trying to find if nasal sprays can help children with snoring, and whether this can reduce the need for surgery.

The 2 groups in the trial

  • Intranasal SteroidsTreatment being tested

    Treatment: Mometasone Furoate 50mcg Nasal Spray

  • Intranasal SalinePlacebo, for comparison

    Treatment: Sodium Chloride 0.9 % Nasal Spray

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Efficacy of Intranasal Steroid for Children With Sleep-Disordered Breathing Non-Responsive to Initial Treatment With Intranasal Saline: A Randomized Trial
Publications
Record updated
30 September 2025